

Claudio Cerchione

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6752147/publications.pdf>

Version: 2024-02-01

139
papers

1,442
citations

516710

16
h-index

552781

26
g-index

143
all docs

143
docs citations

143
times ranked

2424
citing authors

#	ARTICLE	IF	CITATIONS
1	A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. <i>Journal of Hematology and Oncology</i> , 2020, 13, 126.	17.0	135
2	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. <i>Frontiers in Oncology</i> , 2021, 11, 656218.	2.8	63
3	CAR-T cell therapy: a potential new strategy against prostate cancer. , 2019, 7, 258.		61
4	A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2150.	4.1	60
5	Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma. <i>Annals of Hematology</i> , 2017, 96, 627-637.	1.8	45
6	Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. <i>Annals of Hematology</i> , 2018, 97, 1009-1018.	1.8	44
7	IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 639387.	2.8	39
8	The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents. <i>Blood Cancer Journal</i> , 2017, 7, 649.	6.2	37
9	Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments. <i>Frontiers in Oncology</i> , 2020, 10, 624661.	2.8	35
10	18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma. <i>Clinical Nuclear Medicine</i> , 2015, 40, 303-308.	1.3	30
11	ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients. <i>Cell Transplantation</i> , 2020, 29, 096368972096874.	2.5	26
12	PET/CT in Multiple Myeloma: Beyond FDG. <i>Frontiers in Oncology</i> , 2020, 10, 622501.	2.8	24
13	Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. <i>Oncologist</i> , 2018, 23, 454-460.	3.7	22
14	A Frontline Approach With Peripherally Inserted Versus Centrally Inserted Central Venous Catheters for Remission Induction Chemotherapy Phase of Acute Myeloid Leukemia: A Randomized Comparison. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e184-e194.	0.4	22
15	Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. <i>Supportive Care in Cancer</i> , 2017, 25, 839-845.	2.2	20
16	Enasidenib and ivosidenib in AML. <i>Minerva Medica</i> , 2020, 111, 411-426.	0.9	20
17	Contribution of Macrophages and T Cells in Skeletal Metastasis. <i>Cancers</i> , 2020, 12, 1014.	3.7	19
18	Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease. <i>Journal of Medical Virology</i> , 2021, 93, 124-126.	5.0	18

#	ARTICLE	IF	CITATIONS
19	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. <i>Haematologica</i> , 2020, 106, 291-294.	3.5	17
20	Personalized Survival Prediction of Patients With Acute Myeloblastic Leukemia Using Gene Expression Profiling. <i>Frontiers in Oncology</i> , 2021, 11, 657191.	2.8	17
21	CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2639.	3.7	17
22	Safety of FLT3 inhibitors in patients with acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 851-865.	2.2	17
23	Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia. <i>Cancer Medicine</i> , 2017, 6, 1500-1511.	2.8	14
24	FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives. <i>Minerva Medica</i> , 2020, 111, 427-442.	0.9	14
25	Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. <i>Supportive Care in Cancer</i> , 2015, 23, 301-302.	2.2	13
26	Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA). <i>Annals of Hematology</i> , 2015, 94, 531-534.	1.8	12
27	Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone. <i>Supportive Care in Cancer</i> , 2016, 24, 4835-4837.	2.2	12
28	KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients. <i>Annals of Hematology</i> , 2020, 99, 2903-2909.	1.8	12
29	Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens. <i>Frontiers in Oncology</i> , 2021, 11, 643490.	2.8	12
30	Secondary syphilis mimicking malignancy: A case report and review of literature. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 576-578.	1.7	11
31	Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model. <i>Cells</i> , 2020, 9, 2666.	4.1	11
32	Monoclonal antibodies in multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 21-27.	0.8	11
33	Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis. <i>Annals of Hematology</i> , 2017, 96, 697-699.	1.8	10
34	Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support. <i>Supportive Care in Cancer</i> , 2019, 27, 1587-1588.	2.2	10
35	Hydroxychloroquine as Prophylaxis for COVID-19: A Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 605185.	3.5	10
36	Chemotherapy-based regimens in multiple myeloma in 2020. <i>Panminerva Medica</i> , 2021, 63, 7-12.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. <i>Cancers</i> , 2021, 13, 4566.	3.7	10
38	CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia. <i>Minerva Medica</i> , 2020, 111, 455-466.	0.9	10
39	Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future. <i>Minerva Medica</i> , 2020, 111, 395-410.	0.9	10
40	Vitiligo-like lesions in an adult patient treated with Imatinib mesylate. <i>Leukemia Research</i> , 2009, 33, e104-e105.	0.8	9
41	The Molecular Pathogenesis of Multiple Myeloma. <i>Hematology Reports</i> , 2020, 12, 9054.	0.8	9
42	Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 632231.	2.8	8
43	Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope. <i>Minerva Medica</i> , 2020, 111, 467-477.	0.9	8
44	Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis. <i>Cancer Medicine</i> , 2019, 8, 2802-2809.	2.8	7
45	Treatment-Free Remission in Chronic Myeloid Leukemia: Lights and Shadows. <i>Hematology Reports</i> , 2020, 12, 8950.	0.8	7
46	Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art. <i>Frontiers in Oncology</i> , 2020, 10, 592487.	2.8	7
47	PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial. <i>Annals of Hematology</i> , 2021, 100, 1525-1535.	1.8	7
48	Autologous stem cell transplantation in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 220-224.	0.8	7
49	How I Manage Frontline Transplant-Ineligible Multiple Myeloma. <i>Hematology Reports</i> , 2020, 12, 8956.	0.8	6
50	ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study. <i>American Journal of Hematology</i> , 2020, 95, 1030-1037.	4.1	6
51	Urinary Biomarkers in Tumors: An Overview. <i>Methods in Molecular Biology</i> , 2021, 2292, 3-15.	0.9	6
52	Old and new generation proteasome inhibitors in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 193-206.	0.8	6
53	Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684396.	2.8	6
54	Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. <i>Cell Biology and Toxicology</i> , 2023, 39, 795-811.	5.3	6

#	ARTICLE	IF	CITATIONS
55	Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic. <i>Insights Into Imaging</i> , 2020, 11, 129.	3.4	6
56	Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes. <i>Supportive Care in Cancer</i> , 2022, 30, 2293-2298.	2.2	6
57	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. <i>Hematological Oncology</i> , 2022, 40, 704-715.	1.7	6
58	Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. <i>Panminerva Medica</i> , 2021, 63, 1-6.	0.8	5
59	Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia. <i>PLoS ONE</i> , 2021, 16, e0247093.	2.5	5
60	Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis. <i>Frontiers in Oncology</i> , 2020, 10, 624573.	2.8	5
61	Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2017, 17, 105-110.	0.7	5
62	Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia. <i>Minerva Medica</i> , 2020, 111, 386-394.	0.9	5
63	Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 820768.	2.8	5
64	Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. <i>Hematological Oncology</i> , 2022, 40, 987-998.	1.7	5
65	Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma. <i>Case Reports in Hematology</i> , 2016, 2016, 1-3.	0.4	4
66	Salvage therapy with pegylated liposomal doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.. <i>European Journal of Haematology</i> , 2016, 96, 544-544.	2.2	4
67	Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 715-718.	2.5	4
68	How I Treat Relapsed and/or Refractory Multiple Myeloma. <i>Hematology Reports</i> , 2020, 12, 8955.	0.8	4
69	Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 395.	2.4	4
70	Old and new generation immunomodulatory drugs in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 207-219.	0.8	4
71	BCMA-targeting approaches for treatment of multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 28-36.	0.8	4
72	New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. <i>Minerva Medica</i> , 2020, 111, 478-490.	0.9	4

#	ARTICLE	IF	CITATIONS
73	Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection. <i>Cancers</i> , 2022, 14, 1173.	3.7	4
74	A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 505-507.	0.5	3
75	Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on the role of 1,3- β -D-glucan antigenemia and multiphasic contrast-enhanced computed tomography. <i>Supportive Care in Cancer</i> , 2018, 26, 1691-1694.	2.2	3
76	The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 791-799.	2.4	3
77	Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?. <i>Panminerva Medica</i> , 2021, 62, 234-243.	0.8	3
78	Safety and comfort of domestic bortezomib injection in real-life experience. <i>Supportive Care in Cancer</i> , 2018, 26, 3111-3116.	2.2	2
79	How We Manage Smoldering Multiple Myeloma. <i>Hematology Reports</i> , 2020, 12, 8951.	0.8	2
80	Correspondence in reference to previously published manuscript: "Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma. <i>Eur J Haematol</i> . 2020; 105: 667-671". <i>European Journal of Haematology</i> , 2021, 106, 734-736.	2.2	2
81	CAR T cells targeting options in the fight against multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 37-45.	0.8	2
82	Acute leukemias in 2020: state of the art. <i>Minerva Medica</i> , 2020, 111, 384-385.	0.9	2
83	Front-Line Vascular Access Devices in Acute Leukemias " Peripherally Inserted Central Catheter (PICC) Versus Traditional Central Venous Catheter (CVC): A Phase IV Randomized Trial (NCT02405728). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S396-S397.	0.4	1
84	An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia. <i>Anti-Cancer Drugs</i> , 2020, 31, 67-72.	1.4	1
85	Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?. <i>Medicine (United States)</i> , 2020, 99, e21440.	1.0	1
86	Current and future perspectives of maintenance therapy in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 225-233.	0.8	1
87	Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 13-20.	0.8	1
88	Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma. <i>Supportive Care in Cancer</i> , 2021, 29, 6973-6980.	2.2	1
89	Abstract 2651: Deep hypoxia and the genomic background cooperate to shape the metabolic profile of acute myeloid leukemia cells. , 2019, , .		1
90	Abstract 5279: Metabolic profiling defines a new characterization of acute myeloid leukemia and identifies NPM1-mutated cases as a distinct subgroup. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
91	ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study. <i>Blood</i> , 2019, 134, 1565-1565.	1.4	1
92	Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, e19522-e19522.	1.6	1
93	Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy. <i>Journal of Clinical Oncology</i> , 2019, 37, e18313-e18313.	1.6	1
94	Pegfilgrastim versus filgrastim in the supportive care of heavily pretreated multiple myeloma in treatment with pomalidomide-dexamethasone. <i>Journal of Clinical Oncology</i> , 2020, 38, e20514-e20514.	1.6	1
95	P-187 Combination of deferasirox and deferoxamine in management of iron overload in myelodysplastic syndromes (MDS): An update in a hepatopatic patient. <i>Leukemia Research</i> , 2013, 37, S108.	0.8	0
96	P-165 Erythropoietic aspects in MDS patients responders to ESAs treatment. <i>Leukemia Research</i> , 2013, 37, S98.	0.8	0
97	208 MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS: EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE. <i>Leukemia Research</i> , 2015, 39, S104.	0.8	0
98	Full Standard Doses of Lenalidomide in Bortezomib-Refractory Multiple Myeloma Patients Affected by Renal Failure: A Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S342-S343.	0.4	0
99	Bendamustine-Bortezomib-Dexametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S343.	0.4	0
100	Lenalidomide at the Dose of Twenty-five mg Every Other Day in Patients Affected by Multiple Myeloma and Renal Failure: A Real-life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e122.	0.4	0
101	Bendamustine-Bortezomib-Dexamethasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e60-e61.	0.4	0
102	Impact on survival of early detection of recurrence in the follow-up of high risk Hodgkin lymphoma in first complete remission. <i>Hematological Oncology</i> , 2017, 35, 311-311.	1.7	0
103	Reply to the letter to the editor "chronic disseminated candidiasis" by Kenneth Rolston. <i>Supportive Care in Cancer</i> , 2017, 25, 1045-1046.	2.2	0
104	Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure. <i>Anti-Cancer Drugs</i> , 2018, 29, 371-372.	1.4	0
105	Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S256.	0.4	0
106	Combined Oral Administration of Analgesia and Anxiolysis for Pain Associated with Bone Marrow Aspiration and Biopsy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S303.	0.4	0
107	Bendamustine-Bortezomib-Dexamethasone in Heavily Pretreated Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S254-S255.	0.4	0
108	Pegfilgrastim versus Filgrastim in the Management of Therapy-Related Neutropenia in Relapsed and Refractory Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S255-S256.	0.4	0

#	ARTICLE	IF	CITATIONS
109	Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment With Pomalidomide-Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e358.	0.4	0
110	Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in Novel Agents' Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e359-e360.	0.4	0
111	Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e358-e359.	0.4	0
112	How I manage frontline transplant-eligible multiple myeloma in Italy. <i>Hematology Reports</i> , 2020, 12, 8954.	0.8	0
113	What Influences the Choice of Ibrutinib vs Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?. <i>Cell Transplantation</i> , 2020, 29, 096368972095020.	2.5	0
114	MM-385: Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S310.	0.4	0
115	MM-390: Pegfilgrastim vs. Filgrastim in the Supportive Care of Heavily Pre-Treated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S311-S312.	0.4	0
116	MDS-391: Role of Erythropoiesis-Stimulating Agents (ESAs) in Supportive Care of Low-Risk Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S324-S325.	0.4	0
117	Multiple myeloma in 2020: state of the art. <i>Panminerva Medica</i> , 2021, 62, 191-192.	0.8	0
118	Randomized Comparison of Power Doppler Ultrasonography-Guided Core-Needle Biopsy with Open Surgical Biopsy for the Characterization of Lymphadenopathies in Patients with Suspected Lymphoma. <i>Blood</i> , 2016, 128, 685-685.	1.4	0
119	Bendamustine-Bortezomib-Desametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma : A REAL-Life Experience. <i>Blood</i> , 2016, 128, 5713-5713.	1.4	0
120	Adding Hydroxyurea in Combination with Ruxolitinib Improves Clinical Responses in Hyperproliferative Forms of Myelofibrosis. <i>Blood</i> , 2018, 132, 4290-4290.	1.4	0
121	Pegfilgrastim Versus Filgrastim in the Management of Therapy-Related Neutropenia in Relapsed and Refractory Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone. <i>Blood</i> , 2018, 132, 5905-5905.	1.4	0
122	Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma. <i>Blood</i> , 2018, 132, 5648-5648.	1.4	0
123	Blinatumomab is safe and effective in relapsed and MRD-positive B-ALL CD19+ patients: The Bologna Compassionate Program Experience.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18522-e18522.	1.6	0
124	Effect of Oral Iron Treatment in Tmprss6 Knock-out Mouse Model. <i>Blood</i> , 2019, 134, 2235-2235.	1.4	0
125	Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: Old/new in novel agents' era.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20517-e20517.	1.6	0
126	An Innovative Organization Model to Face Risks Reduction Challenges in an Italian Cancer Center During the COVID-19 Pandemic: A Risk Reduction Estimation Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
127	Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease. <i>Blood Transfusion</i> , 2018, 16, 32-35.	0.4	0
128	Dissecting the Adaptive Response to Arginine Deprivation in Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 4497-4497.	1.4	0
129	Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 5020-5020.	1.4	0
130	A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Clinical Practice. <i>Blood</i> , 2020, 136, 32-34.	1.4	0
131	Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL Agents' Era. <i>Blood</i> , 2020, 136, 2-3.	1.4	0
132	Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 2-2.	1.4	0
133	Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone. <i>Blood</i> , 2020, 136, 18-18.	1.4	0
134	Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients. <i>Blood</i> , 2020, 136, 37-38.	1.4	0
135	Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma. <i>Blood</i> , 2020, 136, 1-1.	1.4	0
136	Abstract 3100: Blinatumomab is safe and effective in relapsed and MRD positive B-ALL CD19+ patients: The bologna compassionate program experience. , 2019, , .		0
137	Addition of carfilzomib as a third agent in lenalidomide-refractory multiple myeloma: Switching from doublet to triplet.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20002-e20002.	1.6	0
138	Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. <i>Cancers</i> , 2022, 14, 3012.	3.7	0
139	Hematologic improvements with ivosidenib + azacitidine compared to placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7042-7042.	1.6	0